Identification of a novel allosteric GLP-1R antagonist HTL26119 using structure- based drug design

Bioorg Med Chem Lett. 2019 Oct 15;29(20):126611. doi: 10.1016/j.bmcl.2019.08.015. Epub 2019 Aug 9.

Abstract

A series of novel allosteric antagonists of the GLP-1 receptor (GLP-1R), exemplified by HTL26119, are described. SBDD approaches were employed to identify HTL26119, exploiting structural understanding of the allosteric binding site of the closely related Glucagon receptor (GCGR) (Jazayeri et al., 2016) and the homology relationships between GCGR and GLP-1R. The region around residue C3476.36b of the GLP-1R receptor represents a key difference from GCGR and was targeted for selectivity for GLP-1R.

Keywords: Allosteric antagonist; GCGR; GLP-1R; HTL26119.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allosteric Regulation / drug effects
  • Allosteric Site
  • Amino Acid Sequence
  • Drug Design
  • Glucagon-Like Peptide-1 Receptor / antagonists & inhibitors*
  • Heterocyclic Compounds / chemistry*
  • Molecular Docking Simulation
  • Molecular Structure
  • Protein Binding
  • Receptors, Glucagon / antagonists & inhibitors
  • Signal Transduction
  • Structure-Activity Relationship

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Heterocyclic Compounds
  • Receptors, Glucagon